arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Aquestive Therapeutics, Inc.

AQST
$3.94 ▲ +0.02 (+0.64%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
38 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
53
Health
Fair
Neutral
auto_awesome

Analytical Summary

Aquestive Therapeutics, Inc. shows mixed fundamentals. However, watch Operating Margin (%) and Profit Margin (%) which show concerning trends. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $483.1M
Dividend Yield
Revenue Growth 65.7%
Op. Margin -29.1%
ROIC -38.4%
FCF / Share $-0.12
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -1.32
info Valuation on last close. End-of-day price, Aug 7, 2026.

38-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$14.45M
↑ +65.7%
Net Income Profit after all expenses
$-8.06M
↑ +64.9%
Operating Margin Operating profit as % of sales
-29.1%
↑ +86.9% 1th
FCF / Share Free cash flow per share
$-0.12
↑ +50.8%
Long-Term Debt Long-term obligations
$45.00M
— 0.0%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
100
Financial Health
64
Cash Quality
45

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 38 quarters